Human ES-derived cardiomyocytes regenerate non-human primate hearts

ceazon

) e; \* y3 E# ?% h& P( V% _
& d% }( z- J) R# ]2 x/ `1 N

  X" ~' u( p- }* ^0 \+ ]
# r" e' b3 o/ ]2 G6 ]5 DHuman embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts; h0 z- M4 E/ ?2 m7 Z

1 ]+ P; M. d$ Y7 M 4 X* p2 \( S. `: i
- R0 G. T# v% D7 h+ I0 Z
Pluripotent stem cells provide a potential solution to current epidemic rates of heart failure1 by providing human cardiomyocytes to support heart regeneration2. Studies of human embryonic-stem-cell-derived cardiomyocytes (hESC-CMs) in small-animal models have shown favourable effects of this treatment. However, it remains unknown whether clinical-scale hESC-CM transplantation is feasible, safe or can provide sufficient myocardial regeneration. Here we show that hESC-CMs can be produced at a clinical scale (more than one billion cells per batch) and cryopreserved with good viability. Using a non-human primate model of myocardial ischaemia followed by reperfusion, we show that that cryopreservation and intra-myocardial delivery of one billion hESC-CMs generates extensive remuscularization of the infarcted heart. The hESC-CMs showed progressive but incomplete maturation over a 3-month period. Grafts were perfused by host vasculature, and electromechanical junctions between graft and host myocytes were present within 2 weeks of engraftment. Importantly, grafts showed regular calcium transients that were synchronized to the host electrocardiogram, indicating electromechanical coupling. In contrast to small-animal models7, non-fatal ventricular arrhythmias were observed in hESC-CM-engrafted primates. Thus, hESC-CMs can remuscularize substantial amounts of the infarcted monkey heart. Comparable remuscularization of a human heart should be possible, but potential arrhythmic complications need to be overcome.

bubble_w

求原文

cortex

原文